Kadcyla — Competitive Intelligence Brief

Kadcyla (trastuzumab-emtansine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibody-drug conjugate. Area: Oncology.

marketed Antibody-drug conjugate Receptor tyrosine-protein kinase erbB-2 Oncology Monoclonal antibody

Target snapshot

Kadcyla (trastuzumab-emtansine) — Roche. Trastuzumab emtansine is a HER2-targeted antibody-drug conjugate that works by binding to the HER2 receptor and releasing a cytotoxic agent.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Kadcyla TARGET	trastuzumab-emtansine	Roche	marketed	Antibody-drug conjugate	Receptor tyrosine-protein kinase erbB-2	2013-01-01
Margenza	MARGETUXIMAB	Macrogenics Inc	marketed	HER2/neu Receptor Antagonist [EPC]	Receptor tyrosine-protein kinase erbB-2	2020-01-01
Enhertu	trastuzumab-deruxtecan	Daiichi Sankyo	marketed		Receptor tyrosine-protein kinase erbB-2	2019-01-01
Perjeta	pertuzumab	Roche	marketed	HER2/neu Receptor Antagonist [EPC]	Receptor tyrosine-protein kinase erbB-2	2012-01-01
Gleevec	imatinib	Novartis	marketed	Kinase Inhibitor	Receptor tyrosine-protein kinase erbB-2	2001-01-01
Enhertu	Enhertu	Washington D.C. Veterans Affairs Medical Center	marketed		DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2
Trastuzumab (Herceptin)	trastuzumab-herceptin	Pfizer Inc.	marketed		Receptor tyrosine-protein kinase erbB-2

Recent regulatory actions (last 90 days)

• 2026-03-26 — Kadcyla · FDA · approved · US · Roche

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibody-drug conjugate class)

1. Amgen · 1 drug in this class
2. Hellenic Cooperative Oncology Group · 1 drug in this class
3. Roche · 1 drug in this class
4. SEAGEN · 1 drug in this class
5. Sanofi · 1 drug in this class
6. Sung-Soo Park · 1 drug in this class